Literature DB >> 24727493

Pioglitazone reduces angiotensin II-induced COX-2 expression through inhibition of ROS production and ET-1 transcription in vascular cells from spontaneously hypertensive rats.

Jose V Pérez-Girón1, Roberto Palacios1, Angela Martín1, Raquel Hernanz1, Andrea Aguado2, Sonia Martínez-Revelles2, María T Barrús1, Mercedes Salaices2, María J Alonso3.   

Abstract

Glitazones have anti-inflammatory properties by interfering with the transcription of proinflammatory genes, such as cyclooxygenase (COX)-2, and with ROS production, which are increased in hypertension. This study analyzed whether pioglitazone modulates COX-2 expression in hypertension by interfering with ROS and endothelin (ET)-1. In vivo, pioglitazone (2.5 mg·kg(-1)·day(-1), 28 days) reduced the greater levels of COX-2, pre-pro-ET-1, and NADPH oxidase (NOX) expression and activity as well as O2 (·-) production found in aortas from spontaneously hypertensive rats (SHRs). ANG II increased COX-2 and pre-pro-ET-1 levels more in cultured vascular smooth muscle cells from hypertensive rats compared with normotensive rats. The ETA receptor antagonist BQ-123 reduced ANG II-induced COX-2 expression in SHR cells. ANG II also increased NOX-1 expression, NOX activity, and superoxide production in SHR cells; the selective NOX-1 inhibitor ML-171 and catalase reduced ANG II-induced COX-2 and ET-1 transcription. ANG II also increased c-Jun transcription and phospho-JNK1/2, phospho-c-Jun, and p65 NF-κB subunit nuclear protein expression. SP-600125 and lactacystin, JNK and NF-κB inhibitors, respectively, reduced ANG II-induced ET-1, COX-2, and NOX-1 levels and NOX activity. Pioglitazone reduced the effects of ANG II on NOX activity, NOX-1, pre-pro-ET-1, COX-2, and c-Jun mRNA levels, JNK activation, and nuclear phospho-c-Jun and p65 expression. In conclusion, ROS production and ET-1 are involved in ANG II-induced COX-2 expression in SHRs, explaining the greater COX-2 expression observed in this strain. Furthermore, pioglitazone inhibits ANG II-induced COX-2 expression likely by interfering with NF-κB and activator protein-1 proinflammatory pathways and downregulating ROS production and ET-1 transcription, thus contributing to the anti-inflammatory properties of glitazones.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  angiotensin II; cyclooxygenase-2; endothelin-1; hypertension; peroxisome proliferator-activated receptor-γ; reactive oxygen species

Mesh:

Substances:

Year:  2014        PMID: 24727493     DOI: 10.1152/ajpheart.00924.2013

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  9 in total

Review 1.  Interplay between the renin-angiotensin system, the canonical WNT/β-catenin pathway and PPARγ in hypertension.

Authors:  Alexandre Vallée; Bernard L Lévy; Jacques Blacher
Journal:  Curr Hypertens Rep       Date:  2018-06-09       Impact factor: 5.369

2.  Toll-like receptor 4 contributes to vascular remodelling and endothelial dysfunction in angiotensin II-induced hypertension.

Authors:  R Hernanz; S Martínez-Revelles; R Palacios; A Martín; V Cachofeiro; A Aguado; L García-Redondo; M T Barrús; P R de Batista; A M Briones; M Salaices; M J Alonso
Journal:  Br J Pharmacol       Date:  2015-04-10       Impact factor: 8.739

Review 3.  Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents.

Authors:  Antonino Di Pino; Ralph A DeFronzo
Journal:  Endocr Rev       Date:  2019-12-01       Impact factor: 19.871

4.  Pioglitazone, a PPARγ agonist, attenuates PDGF-induced vascular smooth muscle cell proliferation through AMPK-dependent and AMPK-independent inhibition of mTOR/p70S6K and ERK signaling.

Authors:  Islam Osman; Lakshman Segar
Journal:  Biochem Pharmacol       Date:  2015-11-28       Impact factor: 5.858

5.  Hu antigen R is required for NOX-1 but not NOX-4 regulation by inflammatory stimuli in vascular smooth muscle cells.

Authors:  Andrea Aguado; Thierry Fischer; Cristina Rodríguez; Adrian Manea; José Martínez-González; Rhian M Touyz; Raquel Hernanz; M Jesús Alonso; Dan A Dixon; Ana M Briones; Mercedes Salaices
Journal:  J Hypertens       Date:  2016-02       Impact factor: 4.844

Review 6.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951

Review 7.  Dysfunction of Cerebrovascular Endothelial Cells: Prelude to Vascular Dementia.

Authors:  Feixue Wang; Yu Cao; Lina Ma; Hui Pei; Wolf Dieter Rausch; Hao Li
Journal:  Front Aging Neurosci       Date:  2018-11-16       Impact factor: 5.750

8.  Induction of Cyclooxygenase-2 by Overexpression of the Human NADPH Oxidase 5 (NOX5) Gene in Aortic Endothelial Cells.

Authors:  Javier Marqués; Adriana Cortés; Álvaro Pejenaute; Eduardo Ansorena; Gloria Abizanda; Felipe Prósper; Juan José Martínez-Irujo; Carlos de Miguel; Guillermo Zalba
Journal:  Cells       Date:  2020-03-06       Impact factor: 6.600

9.  Pioglitazone Modulates the Vascular Contractility in Hypertension by Interference with ET-1 Pathway.

Authors:  Roberto Palacios-Ramírez; Raquel Hernanz; Angela Martín; José V Pérez-Girón; María T Barrús; Zoe González-Carnicero; Andrea Aguado; Frederic Jaisser; Ana M Briones; Mercedes Salaices; María J Alonso
Journal:  Sci Rep       Date:  2019-11-11       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.